PURPOSE: We sought to determine whether placing empty catheters within the prostate and then inverse planning iodine-125 seed locations within those catheters (High Dose Rate-Emulating Low Dose Rate Prostate Brachytherapy [HELP] technique) would improve concordance between planned and achieved dosimetry compared with a standard intraoperative technique.
METHODS AND MATERIALS: We examined 30 consecutive low dose rate prostate cases performed by standard intraoperative technique of planning followed by needle placement/seed deposition and compared them to 30 consecutive low dose rate prostate cases performed by the HELP technique. The primary endpoint was concordance between planned percentage of the clinical target volume that receives at least 100% of the prescribed dose/dose that covers 90% of the volume of the clinical target volume (V100/D90) and the actual V100/D90 achieved at Postoperative Day 1.
RESULTS: The HELP technique had superior concordance between the planned target dosimetry and what was actually achieved at Day 1 and Day 30. Specifically, target D90 at Day 1 was on average 33.7 Gy less than planned for the standard intraoperative technique but was only 10.5 Gy less than planned for the HELP technique (p < 0.001). Day 30 values were 16.6 Gy less vs. 2.2 Gy more than planned, respectively (p = 0.028). Day 1 target V100 was 6.3% less than planned with standard vs. 2.8% less for HELP (p < 0.001). There was no significant difference between the urethral and rectal concordance (all p > 0.05).
CONCLUSIONS: Placing empty needles first and optimizing the plan to the known positions of the needles resulted in improved concordance between the planned and the achieved dosimetry to the target, possibly because of elimination of errors in needle placement.
Written by:
Niedermayr TR, Nguyen PL, Murciano-Goroff YR, Kovtun KA, Neubauer Sugar E, Cail DW, O'Farrell DA, Hansen JL, Cormack RA, Buzurovic I, Wolfsberger LT, O'Leary MP, Steele GS, Devlin PM, Orio PF 3rd. Are you the author?
Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA.
Reference: Brachytherapy. 2014 Mar 5. pii: S1538-4721(14)00037-3.
doi: 10.1016/j.brachy.2014.01.009
PubMed Abstract
PMID: 24613569
UroToday.com Prostate Cancer Section